Rigel Pharmaceuticals (RIGL) has recently unveiled its financial performance for the second quarter of 2026, showcasing a robust increase in product sales and an upward revision of its revenue projections. A pivotal aspect of the company's strategy revolves around the impending market introduction of VEPPANU, an innovative Proteolysis Targeting Chimera (PROTAC) designed for breast cancer treatment, slated for mid-August. This strategic move is poised to significantly bolster Rigel's commercial portfolio, solidifying its position as a burgeoning entity within the oncology and hematology sectors.
During the Q2 2026 earnings call, key executives, including President and CEO Raul Rodriguez, Chief Commercial Officer David Santos, Chief Financial Officer Dean Schorno, and Chief Medical Officer Alison Hannah, provided comprehensive insights. The company reported total revenues of $78.7 million, with net product sales reaching $67.0 million—a 14% year-over-year increase. This growth was fueled by strong performances from TAVALISSE ($47.4 million, up 18%) and REZLIDHIA ($8.9 million, up 27%), despite a slight decrease in GAVRETO sales. Contract revenues also saw an increase to $11.7 million, driven by international collaborations and a regulatory milestone payment from Kissei Pharmaceutical for olutasidenib.
The strategic acquisition of VEPPANU, a pioneering FDA-approved PROTAC for advanced breast cancer patients with ESR1 mutations, marks a significant milestone. This drug targets a critical unmet need, offering a novel mechanism of action with promising clinical data. The VERITAC-2 trial demonstrated superior progression-free survival (PFS) of 5.0 months for VEPPANU compared to 2.1 months for fulvestrant, alongside a manageable safety profile. Rigel anticipates VEPPANU will become its leading revenue generator, capitalizing on its unique differentiation and strong efficacy in the substantial second-line ESR1-mutated metastatic breast cancer market, estimated at over $1 billion in the U.S.
Rigel's development pipeline also continues to advance, with a strong focus on R289, a dual IRAK1 and IRAK4 inhibitor for lower-risk myelodysplastic syndrome (MDS). Preliminary Phase 1b data for R289 indicated encouraging safety and efficacy, with 33% of evaluable patients achieving red blood cell transfusion independence. The company plans to complete dose expansion enrollment for R289 and select a Phase 2 dose by year-end, with potential for significant market opportunities in various indications. Additionally, collaborations are ongoing for olutasidenib in IDH1-mutated AML and other hematologic malignancies.
Rigel's financial discipline and strategic initiatives have transformed it into a profitable multi-product company since 2020. The increased revenue guidance for 2026, ranging from $285 million to $295 million, underscores confidence in sustained growth. The company’s focus on the successful commercialization of VEPPANU, alongside the progression of its pipeline assets like R289, positions it for continued expansion and long-term shareholder value creation in the dynamic biotechnology landscape.
